Drug Profile
Daclizumab biosimilar - Sunshine Guojian Pharmaceutical
Alternative Names: Interleukin-2 receptor antagonist - Sunshine Guojian Pharmaceutical; XenopaxLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Shanghai CP Guojian Pharmaceutical
- Developer Sunshine Guojian Pharmaceutical
- Class Anti-inflammatories; Antiasthmatics; Antihyperglycaemics; Antineoplastics; Antipsoriatics; Antivirals; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Interleukin 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Renal transplant rejection
- No development reported Multiple sclerosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Multiple-sclerosis in China (IV, Injection)
- 01 Jan 2012 Clinical trials in Multiple sclerosis in China (IV)
- 31 Dec 2011 Launched for Rheumatoid arthritis (prevention) in China (IV)